<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MEF2B (Myocyte Enhancer Factor 2B)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>MEF2B</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>MEF2B (Myocyte Enhancer Factor 2B)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=MEF2B" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
MEF2B (Myocyte Enhancer Factor 2B) encodes a transcription factor belonging to the MADS (MEF2, Agamous, Deficiens, serum response factor) box family of DNA-binding proteins. Located on chromosome 19p13.11, MEF2B is a member of the myocyte-specific enhancer factor 2 (MEF2) family, which also includes [MEF2A](/genes/mef2a), [MEF2C](/genes/mef2c), and [MEF2D](/genes/mef2d) [@mef2b_ncbi]. The MEF2 family proteins are ancient and conserved regulatory factors that control diverse developmental programs, particularly in muscle and neural tissues [@potthoff2007]. While all MEF2 family members share a conserved N-terminal MADS domain that mediates DNA binding and dimerization, they exhibit distinct expression patterns and functional specializations.
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MEF2B (Myocyte Enhancer Factor 2B)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>MEF2B</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>MEF2B (Myocyte Enhancer Factor 2B)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=MEF2B" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
MEF2B (Myocyte Enhancer Factor 2B) encodes a transcription factor belonging to the MADS (MEF2, Agamous, Deficiens, serum response factor) box family of DNA-binding proteins. Located on chromosome 19p13.11, MEF2B is a member of the myocyte-specific enhancer factor 2 (MEF2) family, which also includes [MEF2A](/genes/mef2a), [MEF2C](/genes/mef2c), and [MEF2D](/genes/mef2d) [@mef2b_ncbi]. The MEF2 family proteins are ancient and conserved regulatory factors that control diverse developmental programs, particularly in muscle and neural tissues [@potthoff2007]. While all MEF2 family members share a conserved N-terminal MADS domain that mediates DNA binding and dimerization, they exhibit distinct expression patterns and functional specializations.
MEF2B was originally characterized as a transcriptional regulator of smooth muscle genes, including the smooth muscle myosin heavy chain gene. However, subsequent research has revealed broader functions in lymphocyte development, neural tissues, and oncogenesis. The protein functions as a DNA-binding transcription activator and interacts with histone deacetylases (HDACs) to modulate gene expression programs [@mef2b_ncbi]. Unlike other MEF2 family members, MEF2B exhibits relatively restricted expression in adult tissues, with highest expression in lymphoid tissues, though it is also present in the developing brain and nervous system.
The MEF2B gene is located on chromosome 19 at position p13.11 (GRCh38 coordinates: chr19:16,200,000-16,220,000 approximately). The gene encodes a protein of approximately 365 amino acids, though multiple splice variants may exist. The genomic organization includes the characteristic MADS domain encoded in the N-terminal region, which is highly conserved across all MEF2 family members [@mef2b_ncbi].
The MADS domain (named after the founding members MCM1, Agamous, Deficiens, and Serum Response Factor) spans approximately 56 amino acids and serves dual functions: it mediates dimerization between MEF2 proteins and provides the DNA-binding interface. This domain allows MEF2B to bind to A/T-rich DNA sequences known as MEF2 response elements (MRE), which contain the consensus sequence CTA(A/T)4TAG.
The MEF2B protein possesses the canonical MADS domain structure shared among all MEF2 family members. This domain spans amino acids 1-56 and mediates:
MEF2B functions as a DNA-binding transcription factor that can both activate and repress gene expression, depending on cellular context and interacting partners. In its default state, MEF2B functions as a transcriptional activator, binding to MEF2 response elements in the promoters and enhancers of target genes. However, recruitment of corepressor complexes, particularly class IIa histone deacetylases (HDAC4, HDAC5, HDAC7, and HDAC9), can convert MEF2B into a transcriptional repressor [@tamura2014].
The balance between activation and repression is dynamically regulated by signaling pathways. Calcium influx through NMDA receptors and voltage-gated calcium channels activates calcineurin, which dephosphorylates class IIa HDACs, promoting their nuclear export and relieving repression of MEF2 target genes. This signaling cascade is particularly important in neurons, where activity-dependent gene expression underlies synaptic plasticity and learning [@flavell2008].
MEF2B exhibits broad but relatively specific expression patterns compared to other MEF2 family members. According to RNA-seq data from the Genotype-Tissue Expression (GTEx) project and NCBI databases [@mef2b_ncbi]:
As a transcription factor, MEF2B localizes predominantly to the nucleus, where it binds to DNA response elements and interacts with cofactor complexes. The nuclear localization is mediated by a nuclear localization signal (NLS) within the MADS domain region. Post-translational modifications, particularly phosphorylation, can affect nuclear-cytoplasmic shuttling.
The MEF2 family consists of four highly conserved members (MEF2A, MEF2B, MEF2C, and MEF2D) that arose from gene duplication events early in vertebrate evolution. While all family members share the MADS domain and can bind similar DNA sequences, they have diverged in their expression patterns and functional roles:
The most well-established disease association for MEF2B is with B-cell lymphomas, particularly germinal center (GC)-derived lymphomas including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) [@yang2018].
Molecular Mechanisms:
While MEF2B is less studied in the nervous system compared to MEF2C and MEF2A, emerging evidence suggests roles in neurodevelopment and neuropsychiatric disorders:
Obsessive-Compulsive Disorder (OCD):
GWAS studies have associated MEF2B loci with N-glycosylation of immunoglobulin G, demonstrating links to autoimmune diseases and hematological cancers. Altered MEF2B function may affect immune cell development and function, potentially contributing to autoimmune susceptibility.
The interaction between MEF2B and class IIa histone deacetylases has therapeutic implications for neurodegenerative disorders. HDAC inhibitors have been explored as potential treatments for Alzheimer's disease, Parkinson's disease, and Huntington's disease [@zhang2019]:
Given the frequent MEF2B mutations in B-cell lymphomas, therapeutic strategies targeting MEF2B or its transcriptional targets are being explored:
MEF2B interacts with several key proteins that modulate its transcriptional activity:
MEF2B integrates signals from multiple signaling pathways:
The broader MEF2 family has been extensively studied in the context of neurodegenerative diseases, and understanding these mechanisms provides context for MEF2B function:
Studies have demonstrated that MEF2 proteins, particularly MEF2A and MEF2C, protect neurons from amyloid-beta ([Aβ](/proteins/amyloid-beta)) toxicity in Alzheimer's disease models. MEF2 activation upregulates expression of anti-apoptotic genes including Bcl-2 and Bcl-xL, while downregulating pro-apoptotic mediators. Although MEF2B's specific role in this context is less characterized, the conservation of these functions across the MEF2 family suggests similar protective mechanisms may operate [@lin2016].
The microtubule-associated protein tau, whose pathological aggregation is a hallmark of Alzheimer's disease and other tauopathies, is subject to transcriptional regulation by MEF2 family members. MEF2 activity modulates expression of tau kinases and phosphatases, potentially influencing tau phosphorylation states. Dysregulation of MEF2-mediated transcription may therefore contribute to tau pathology progression.
MEF2 proteins are critical regulators of synaptic plasticity, controlling expression of genes involved in dendritic spine formation, synapse maturation, and synaptic transmission. In neurodegenerative conditions, MEF2 dysfunction contributes to synaptic loss, a correlate of cognitive decline. The activity-dependent regulation of MEF2 through calcium signaling provides a mechanism by which neural activity maintains synaptic health [@li2020].
Emerging evidence suggests MEF2 family members regulate inflammatory responses in glial cells. MEF2C in microglia influences cytokine production and phagocytic activity, with implications for neuroinflammation in Parkinson's disease and Alzheimer's disease. While MEF2B's role in glial cells is less established, its expression in myeloid lineages suggests potential involvement.
MEF2B connects to multiple pages within the NeuroWiki knowledge base:
MEF2 transcription factors play crucial roles in activity-dependent synaptic plasticity. While MEF2C has been most extensively studied in this context, MEF2B likely contributes to similar mechanisms:
MEF2B sits at the intersection of transcription and epigenetics:
MEF2 proteins respond to various cellular stresses relevant to neurodegeneration:
During brain development, MEF2B contributes to:
MEF2B is a member of the MADS-box transcription factor family with important roles in lymphocyte development and, to a lesser extent, neural tissues. Its frequent mutation in B-cell lymphomas makes it a significant oncogene in germinal center-derived malignancies. In the nervous system, MEF2B likely contributes to transcriptional programs underlying neuronal development and plasticity, though this role is less well-characterized than for MEF2C or MEF2A.
The MEF2 family arose from gene duplication events in vertebrate evolution, with the four paralogs (MEF2A, B, C, D) emerging through whole-genome duplication. This evolutionary history explains the conservation of the MADS domain while allowing functional diversification through changes in expression patterns and protein-protein interaction domains. MEF2B's specialization in lymphoid tissues represents a case of subfunctionalization, where the ancestral developmental regulator was co-opted for immune system functions.
During neural development, MEF2 family members exhibit distinct expression patterns that reflect their specialized functions. MEF2B expression has been detected in neural progenitor cells, where it contributes to proliferation and differentiation decisions [@chen2021]. MEF2 proteins promote neuronal differentiation by activating neuron-specific gene programs while suppressing glial differentiation pathways. In cortical development, MEF2C is the predominant family member, but MEF2B may contribute to specific cortical layer specification. MEF2 expression in the hippocampus regulates genes important for memory consolidation.
Future research directions include: